DA Davidson downgraded Accolade to Neutral from Buy with a price target of $14, down from $16, after assuming coverage of the name. The analyst awaits greater conviction that the company’s 20%+ growth can be sustained towards fiscal 2029’s $1B revenue goal, given Q3’s deceleration to 17% pro-forma growth from Q2’s 19%. The firm believes Accolade is appropriately priced “given the puts/takes to revenue and profitability at present.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACCD:
- A New Cause for Concern: Accolade, Inc. Adds a New Regulation Risk
- Accolade price target raised to $16 from $15 at Truist
- Accolade price target raised to $15 from $12 at Piper Sandler
- Accolade price target raised to $12 from $10 at Wells Fargo
- Accolade backs FY25 revenue view up 20%, consensus $493.01M
